Study pegs certain cellular activities to driving Alzheimer’s disease. Researchers at Washington University School of Medicine in St. Louis have linked disease-related proteins and genes to identify specific cellular pathways responsible for Alzheimer’s genesis and progression.
The DIAN and DIAN-TU are deeply saddened by the recent death of our beloved colleague, Dr. Francisco Lopera, Principal Investigator at our site in Colombia (Grupo Neurociencias de Antioquia – GNA). Alzforum offers this remembrance, highlighting the impact of Dr. Lopera’s work on the AD field.
Alisha J. Daniels, Eric McDade, Jorge J. Llibre-Guerra, Chengjie Xiong, Richard J. Perrin, Laura Ibanez, Charlene Supnet-Bell, Carlos Cruchaga, Alison Goate, Alan E. Renton, Tammie L.S. Benzinger, Brian A. Gordon, Jason Hassenstab, Celeste Karch, Brent Popp, Allan Levey, John Morris, Virginia Buckles, Ricardo F. Allegri, Patricio Chrem, Sarah B. Berman, Jasmeer P. Chhatwal, Martin R. […]
As discussed at the Alzheimer’s Association International Conference in Philadelphia, nearly two dozen mutation carriers who took gantenerumab for eight years had half the risk of developing symptoms as did untreated controls.
Many researchers think the full promise of plaque removal lies in prevention. If plaques were abolished before they could kick off downstream pathologies such as tangles, would the disease be stopped in its tracks?
The soaring burden of dementia threatens global health. Science is paving new paths to solutions.
WashU School of Medicine recently dedicated the new 609,000-square-foot Jeffrey T. Fort Neuroscience Research Building, which houses some 120 research teams — one of the highest concentrations of neuroscientists in the world.
Response to the 28 September 2022 announcement found on Eisai’s website.
Salloway, S., Farlow, M., McDade, E. et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease. Nat Med 27, 1187–1196 (2021). https://doi.org/10.1038/s41591-021-01369-8